Drug Approval | October 19, 2021
MSN Labs launches drug for diabetes management
The company claims that its Empagliflozin tablets are the most affordable in India
The company claims that its Empagliflozin tablets are the most affordable in India
The first patient dosed with VX-880 demonstrated restoration of insulin production and achieved C-peptide of 560 pmol/L in response to Mixed Meal Tolerance Test (MMTT) at Day 90 visit
First anticipated spinout from the alliance, Circle Therapeutics, to develop novel muscle stem cell therapies for a variety of skeletal muscle disorders
Tecentriq is the first and only cancer immunotherapy approved for NSCLC in the adjuvant setting
Ipsen obtains an exclusive license to develop, manufacture and commercialize a pre-clinical stage METTL3-inhibitor programme
The company operates four mid-sized hospitals with a total bed capacity of 556 in eastern India
The export policy of all diagnostic kits and reagents (including instruments /apparatus) ... is being made free with immediate effect," the directorate general of foreign trade (DGFT) said in a notification
Equity raise to finance growth and investments in the biological space
U.S. FDA has accepted the investigational new drug application for phase 1 clinical trial in non-Hodgkin’s lymphoma
Everlife leads the series A round, and SPRIM Global Investments participates in the financing syndicate
Subscribe To Our Newsletter & Stay Updated
